Economic Burden of Adverse Events Associated With Follow-Up Frequency Among Patients With Metastatic Melanoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,828
- 试验地点
- 1
- 主要终点
- Treatment-related and all-cause AE costs for nivolumab/ipilimumab combination therapy for metastatic melanoma
研究概览
简要总结
This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with metastatic melanoma
- •Initiated at least 1 treatment for metastatic melanoma after 2011
- •Continuous enrollment in their healthcare plan for at least 6 months before and at least 6 weeks after the index date
- •Patients who received at least 1 dose of study drug in CA209-067
排除标准
- 未提供
结局指标
主要结局
Treatment-related and all-cause AE costs for nivolumab/ipilimumab combination therapy for metastatic melanoma
时间窗: Approximately 5 years
Treatment-related and all-cause AE costs for nivolumab monotherapy for metastatic melanoma
时间窗: Approximately 5 years
Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with more frequent general outpatient visits
时间窗: Approximately 5 years
Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with less frequent general outpatient visits
时间窗: Approximately 5 years
Treatment-related and all-cause AE costs for ipilimumab monotherapy for metastatic melanoma
时间窗: Approximately 5 years
次要结局
未报告次要终点